Published Guideline
READ GUIDELINE
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer" originally published in Journal for ImmunoTherapy of Cancer (JITC) on June 9, 2023 and has since been updated.
Updated Content (last reviewed 5/25/24)
SITC continually evaluates the field for practice-changing data and new FDA approvals that may affect the guideline. The information on this page provides a detailed overview of updates to the guideline content based on changes in the field. Updates to the guideline outlined below were made with the approval of SITC's Gynecologic Cancer CPG Expert Panel. More information on SITC Guidelines can be found here.
v1.1 Update Summary
The FDA granted approval of pembrolizumab with chemoradiotherapy FIGO 2014 Stage III-IVA cervical cancer on January 12, 2024. Based on this approval, the Gynecologic Cancer CPG has been updated in the following location: Immunotherapy for the treatment of cervical cancer - Recommended immunotherapy treatments for cervical cancer (including Table 2).
The FDA granted approval of dostarlimab with carboplatin and paclitaxel, followed by single-agent dostarlimab for dMMR or MSI-H (as determined by an FDA-approved test) primary advanced or recurrent endometrial cancer on July 31, 2023. Based on this approval, the Gynecologic Cancer CPG has been updated in the following location: Immunotherapy for the treatment of endometrial cancer - Recommended immunotherapy treatments for endometrial cancer (including Table 3).
Updated Figures
- Table 2 – Registrational trial data for ICIs for the treatment of cervical cancer
- Table 3 – Landmark trials and registrational data for ICIs for the treatment of endometrial cancer